We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
Read MoreHide Full Article
Shares of Viking Therapeutics (VKTX - Free Report) fell 6% on Tuesday after pharma giant Eli Lilly (LLY - Free Report) announced the launch of single-dose vials of its popular obesity drug, Zepbound (tirzepatide). These new vials are priced at least 50% lower than the list price of competing GLP-1 medicines for obesity.
A four-week supply of the 2.5 mg vials has been priced at $399 while the same for the 5 mg dose will cost $549. Zepbound is available in a single-dose pen (autoinjector), which is priced at about $1,000 for a month’s supply. The newer versions of the drug will be launched without an autoinjector and patients will require a syringe to inject themselves.
Through this launch, Lilly intends to meet supply shortages for Zepbound, which has been experiencing high demand. The vials should be easier to manufacture than pens and can help improve supply.
These cheaper versions of Zepbound will be available through Lilly’s direct-to-consumer website called LillyDirect for self-pay by patients with a valid on-label prescription. The availability of these vials is expected to broaden access for obesity patients especially those without insurance.
Why Did Lilly’s Move Impact VKTX Stock?
Lilly’s intent to launch these vials seems simple — it wants to strengthen its presence in the obesity market and also lower the use of compounded versions of Zepbound used in several pharmacies, weight loss clinics and medical spas.
While the move does benefit LLY, it sent Viking’s stock down. It seems investors were concerned about the impact of Lilly’s decision on the small biotech whose obesity drug is nearing late-stage development.
Though it does not have any marketed drugs in its portfolio, VKTX is one of the few biotechs that has shown immense potential in the obesity space, all thanks to the treatment potential of its investigational GLP-1 drug VK2735. The drug, which is being evaluated as a subcutaneous (SC) injection and as an oral pill, demonstrated superior weight reduction in clinical studies. While VKTX is making preparations to advance SC formulation to late-stage development, it intends to start a mid-stage study on the oral formulation of the drug in obesity patients before 2024-end.
Year to date, Viking’s shares have skyrocketed 230% against the industry’s 0.1% fall.
Image Source: Zacks Investment Research
Other Players in the GLP-1 Market
Another company with an approved marketed drug that competes with Lilly in the GLP-1 space is Novo Nordisk (NVO - Free Report) . Novo’s semaglutide is approved as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes and as Wegovy injection for weight management. NVO is also working to improve the supply of Wegovy in response to rising demand but has not been as successful as Lilly in its efforts. The launch of these affordable versions of Zepbound could put further pressure on Novo Nordisk.
Amgen (AMGN - Free Report) also has a GLP-1 receptor candidate, MariTide (maridebart cafraglutide), for obesity in its pipeline. Top line 52-week data from the phase II study on MariTide in adults with overweight or obesity is expected in late 2024. AMGN is planning to conduct a comprehensive phase III program on the candidate across obesity, obesity-related conditions and type-II diabetes. It plans to begin a phase II study on the candidate in type II diabetes in late 2024.
Market Potential in the Obesity Drugs Space
Despite the presence of pharma bigwigs like Lilly and Novo in this space, we believe that there is room for small biotechs like Viking Therapeutics, which is still a couple of years from making a regulatory filing for its obesity drug.
Per research conducted by Goldman Sachs, the obesity market in the United States is expected to reach $130 billion by 2030. This is evident from the fact that despite raking in billions from sales of their respective obesity drugs, Lilly and Novo are still unable to cope with existing demand. The firms are not only investing heavily to optimize their respective production capacities but have also started evaluating multiple other novel obesity candidates.
Image: Bigstock
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
Shares of Viking Therapeutics (VKTX - Free Report) fell 6% on Tuesday after pharma giant Eli Lilly (LLY - Free Report) announced the launch of single-dose vials of its popular obesity drug, Zepbound (tirzepatide). These new vials are priced at least 50% lower than the list price of competing GLP-1 medicines for obesity.
A four-week supply of the 2.5 mg vials has been priced at $399 while the same for the 5 mg dose will cost $549. Zepbound is available in a single-dose pen (autoinjector), which is priced at about $1,000 for a month’s supply. The newer versions of the drug will be launched without an autoinjector and patients will require a syringe to inject themselves.
Through this launch, Lilly intends to meet supply shortages for Zepbound, which has been experiencing high demand. The vials should be easier to manufacture than pens and can help improve supply.
These cheaper versions of Zepbound will be available through Lilly’s direct-to-consumer website called LillyDirect for self-pay by patients with a valid on-label prescription. The availability of these vials is expected to broaden access for obesity patients especially those without insurance.
Why Did Lilly’s Move Impact VKTX Stock?
Lilly’s intent to launch these vials seems simple — it wants to strengthen its presence in the obesity market and also lower the use of compounded versions of Zepbound used in several pharmacies, weight loss clinics and medical spas.
While the move does benefit LLY, it sent Viking’s stock down. It seems investors were concerned about the impact of Lilly’s decision on the small biotech whose obesity drug is nearing late-stage development.
Though it does not have any marketed drugs in its portfolio, VKTX is one of the few biotechs that has shown immense potential in the obesity space, all thanks to the treatment potential of its investigational GLP-1 drug VK2735. The drug, which is being evaluated as a subcutaneous (SC) injection and as an oral pill, demonstrated superior weight reduction in clinical studies. While VKTX is making preparations to advance SC formulation to late-stage development, it intends to start a mid-stage study on the oral formulation of the drug in obesity patients before 2024-end.
Year to date, Viking’s shares have skyrocketed 230% against the industry’s 0.1% fall.
Image Source: Zacks Investment Research
Other Players in the GLP-1 Market
Another company with an approved marketed drug that competes with Lilly in the GLP-1 space is Novo Nordisk (NVO - Free Report) . Novo’s semaglutide is approved as Ozempic pre-filled pen and Rybelsus oral tablet for type II diabetes and as Wegovy injection for weight management. NVO is also working to improve the supply of Wegovy in response to rising demand but has not been as successful as Lilly in its efforts. The launch of these affordable versions of Zepbound could put further pressure on Novo Nordisk.
Amgen (AMGN - Free Report) also has a GLP-1 receptor candidate, MariTide (maridebart cafraglutide), for obesity in its pipeline. Top line 52-week data from the phase II study on MariTide in adults with overweight or obesity is expected in late 2024. AMGN is planning to conduct a comprehensive phase III program on the candidate across obesity, obesity-related conditions and type-II diabetes. It plans to begin a phase II study on the candidate in type II diabetes in late 2024.
Market Potential in the Obesity Drugs Space
Despite the presence of pharma bigwigs like Lilly and Novo in this space, we believe that there is room for small biotechs like Viking Therapeutics, which is still a couple of years from making a regulatory filing for its obesity drug.
Per research conducted by Goldman Sachs, the obesity market in the United States is expected to reach $130 billion by 2030. This is evident from the fact that despite raking in billions from sales of their respective obesity drugs, Lilly and Novo are still unable to cope with existing demand. The firms are not only investing heavily to optimize their respective production capacities but have also started evaluating multiple other novel obesity candidates.
Viking Therapeutics, Inc. Price
Viking Therapeutics, Inc. price | Viking Therapeutics, Inc. Quote
VKTX Zacks Rank
Viking Therapeutics currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.